Physician profile
David Rowe
NPI 1629099304
$8,812.21
in general payments reported to CMS, 2019-2025
21 companies · $881 in 2025
The $881 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,771 · 2020: $1,156 · 2021: $568 · 2022: $804 · 2023: $1,159 · 2024: $1,474 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,514.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,174.30 | 2019-2025 | Proclaim, Eterna, Exclaim |
| Boston Scientific Corporation | $1,570.99 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Forte Bio-Pharma LLC | $328.79 | 2020-2024 | Prolate, Nalocet |
| Biodelivery Sciences International, INC. | $114.97 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.46 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $58.77 | 2020-2021 | |
| Pfizer INC. | $56.23 | 2019 | |
| Globus Medical, INC. | $53.40 | 2025 | Senza |
| Sentynl Therapeutics, INC. | $43.30 | 2019 | |
| Kaleo, INC. | $43.29 | 2019 | |
| Bioventus LLC | $39.17 | 2020-2024 | Durolane |
| Spr Therapeutics, INC | $38.74 | 2025 | Sprint Pns System |
| Redhill Biopharma INC. | $37.93 | 2020 | |
| Medtronic, INC. | $26.78 | 2025 | Inceptiv |
| Scilex Pharmaceuticals INC. | $22.53 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $21.89 | 2019 | |
| Medtronic USA, INC. | $21.44 | 2019 | |
| Nevro Corp. | $19.90 | 2019 | |
| Flowonix Medical Incorporated | $17.91 | 2019 | |
| Shionogi INC | $12.09 | 2019 | |
| Lilly USA, LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.